Imatinib Amarox (Imatinib)

Imatinib blocks the activity of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases by occupying their ATP‑binding pockets. This inhibition stops downstream signaling that promotes malignant cell growth, leading to reduced proliferation and increased cell death in tumors that depend on these pathways.

The dosage of Imatinib Amarox is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should determine the appropriate regimen.

Imatinib is classified as contraindicated or to be used only when the potential benefit justifies the potential risk to the fetus. Limited data exist for breastfeeding, and the drug may be excreted in breast milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their physician.

To place an order, submit an enquiry on the Imatinib Amarox product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved for chronic myeloid leukemia and remains a standard first‑line option. Newer agents such as dasatinib and nilotinib offer alternative potency and side‑effect profiles, but Imatinib’s long‑term safety data and cost‑effectiveness make it a widely used choice in many treatment guidelines.

Imatinib Amarox tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Imatinib Amarox is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious adverse events include hepatotoxicity, severe neutropenia, cardiac dysfunction (reduced left ventricular ejection fraction), and significant bleeding. Patients should be monitored regularly with liver function tests, complete blood counts and cardiac assessments, and any new symptoms should be reported promptly.

Imatinib Amarox is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking strong CYP3A4 inducers or inhibitors that cannot be managed clinically.